European Commission logo
English English
CORDIS - EU research results

Reversal of anti-cancer drug resistance

Project description

Targeting mechanisms of cancer drug resistance

Resistance to anticancer therapy represents the main obstacle to successful long-term treatment and recovery of cancer patients. Scandion Oncology from Denmark is developing a new drug (SCO-101) that effectively targets several most common cancer molecular resistance mechanisms. SCO-101 has successfully passed four clinical phase 1 studies in healthy volunteers. The goal of the EU-funded SCANRESIST project is to conduct clinical validation studies in patients with taxane-resistant cancer with open-labelled phase 2 prospective clinical trial to establish SCO-101 proof-of-concept as a safe and efficient treatment modality. SCO-101 represents a paradigm shift acting via multiple mechanisms to interfere with drug resistance.


Worldwide in 2018, cancer has been responsible for around 9.6 million deaths, and with a prediction of a further increase in incidence over the next years – which calls for urgent better treatment modalities to combat such deadly disease. Resistance to anticancer therapy is considered the main obstacle to successful clinical management of cancer patients. Scandion Oncology A/S (SCANDION) is a clinical-stage biotechnology company aimed to solve the anti-cancer drug resistance problem. We are developing a new drug, the SCO-101, which effectively targets some of the most common molecular resistance mechanisms in cancer. SCO-101 represent a paradigm shift in treatment of drug-resistant cancer, with multi mechanisms of actions in interfering with drug resistance. SCO-101 has previously passed four clinical phase I studies in healthy volunteers and proved to be a safe oral drug with very limited toxicity. The SCANRESIST project aims at performing clinical validation studies in taxane resistant breast cancer patients with open-labelled Phase II prospective clinical trial to establish SCO-101 Proof of Concept as a safe and efficient treatment modality.
Our business model is based on out-licensing SCO-101 to pharma players active in anti-cancer drugs – who will be responsible for the remaining clinical development and market launch. The Phase II clinical validation has been pointed as a critical step achieve a deal with big pharma partners/licensees, which we know are interested in novel drugs with novel MoA, and with well-designed and well-performed phase II studies with positive results. Thus, the project will not only open a large market for SCANDION as it will also allow us to position the company as a unique provider of a new generation of anti-cancer resistance drugs – continuing our path on developing other drugs to combat drug resistance in cancer, innovative trial designs, predictive biomarkers and biomarker endpoints.

Call for proposal


See other projects for this call

Sub call



Net EU contribution
€ 50 000,00

See on map


The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Danmark Hovedstaden Byen København
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Total cost
€ 71 429,00